Volume 85 Issue 36 | p. 25 | Concentrates
Issue Date: September 3, 2007

NPIL Mulls Drug Discovery Spin-Off

Department: Business

Mumbai-based Nicholas Piramal India Ltd. is considering whether to turn its drug discovery research unit into a separate entity. Employing many Indian researchers recruited from the U.S., NPIL is one of India's most research-focused pharmaceutical companies. In July, the firm announced that it had an investigational new drug undergoing clinical trials at Harvard University's Dana-Farber Cancer Institute for treatment of multiple myeloma. One of the deadliest forms of cancers, myeloma is so far untreatable for most patients.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment